Prometheus Biosciences adds to board of directors

Fred Hassan was appointed to Prometheus Biosciences’ board of directors, the company announced May 17.

Advertisement

Mr. Hassan is director of private equity company Warburg Pincus, and he was previously chair and CEO of Schering-Plough. He also has experience at Pharmacia Corp., Amgen and Precigen. He received his MBA from Harvard Business School in Boston.

Prometheus Biosciences is a biotechnology company focused on diagnostics and treatment of inflammatory bowel disease and other immune-mediated diseases.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.